InflaRx (NASDAQ:IFRX – Free Report) had its target price hoisted by Guggenheim from $7.00 to $10.00 in a report published on Wednesday morning, Ratings reports. The brokerage currently has a buy ...

Allowing people with state-issued concealed carry licenses or permits to conceal a handgun in any other state, a bill ...

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Patrycja Humienik’s debut poetry collection, “We Contain Landscapes,” explores chronic illness, climate change, borders and ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Semi, a global electronics innovator and Murata company, today announced a breakthrough in multi-level buck regulator technology that promises to revolutionize the mobile battery charging industry.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Siri might have been the original voice assistant but Amazon’s Alexa was the first to break free ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...

About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop ...

About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover ...